{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,12]],"date-time":"2026-07-12T04:20:36Z","timestamp":1783830036077,"version":"3.55.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T00:00:00Z","timestamp":1761696000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T00:00:00Z","timestamp":1761696000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"the Foundation of Chongqing Municipal Education Commission","award":["HZ2021006"],"award-info":[{"award-number":["HZ2021006"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"DOI":"10.1007\/s12032-025-03082-9","type":"journal-article","created":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T05:57:01Z","timestamp":1761717421000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["STXBP6 regulates growth, metastasis and lipid metabolism of ovarian cancer cells via the PI3K\/AKT signaling pathway"],"prefix":"10.1007","volume":"42","author":[{"given":"Min","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hang","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinke","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fengzhen","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siying","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinlong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhu","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,29]]},"reference":[{"key":"3082_CR1","doi-asserted-by":"publisher","first-page":"972","DOI":"10.6004\/jnccn.2022.0047","volume":"20","author":"DK Armstrong","year":"2022","unstructured":"Armstrong DK, Alvarez RD, Backes FJ, Bakkum-Gamez JN, Barroilhet L, Behbakht K, et al. NCCN guidelines\u00ae insights: ovarian cancer, version 3.2022. J Natl Compr Canc Netw. 2022;20:972\u201380.","journal-title":"J Natl Compr Canc Netw"},{"key":"3082_CR2","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1016\/j.ygyno.2020.05.681","volume":"158","author":"G Bogani","year":"2020","unstructured":"Bogani G, Lopez S, Mantiero M, Ducceschi M, Bosio S, Ruisi S, et al. Immunotherapy for platinum-resistant ovarian cancer. Gynecol Oncol. 2020;158:484\u20138.","journal-title":"Gynecol Oncol"},{"key":"3082_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.semcancer.2021.09.002","volume":"77","author":"K El Bairi","year":"2021","unstructured":"El Bairi K, Singh S, Le Page C. Revisiting platinum-resistant ovarian cancer: advances in therapy, molecular biomarkers, and clinical outcomes. Semin Cancer Biol. 2021;77:1\u20132.","journal-title":"Semin Cancer Biol"},{"key":"3082_CR4","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1007\/s11864-020-00747-7","volume":"21","author":"J Glajzer","year":"2020","unstructured":"Glajzer J, Grabowski JP, Sehouli J, Pfisterer J. Recurrent treatment in ovarian cancer patients: what are the best regimens and the order they should be given? Curr Treat Options Oncol. 2020;21:49.","journal-title":"Curr Treat Options Oncol"},{"key":"3082_CR5","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m3773","volume":"371","author":"L Kuroki","year":"2020","unstructured":"Kuroki L, Guntupalli SR. Treatment of epithelial ovarian cancer. BMJ. 2020;371:m3773.","journal-title":"BMJ"},{"key":"3082_CR6","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1038\/s43018-023-00617-9","volume":"4","author":"PA Konstantinopoulos","year":"2023","unstructured":"Konstantinopoulos PA, Matulonis UA. Clinical and translational advances in ovarian cancer therapy. Nat Cancer. 2023;4:1239\u201357.","journal-title":"Nat Cancer"},{"issue":"Suppl 24","key":"3082_CR7","doi-asserted-by":"publisher","first-page":"4563","DOI":"10.1002\/cncr.32595","volume":"125","author":"R Arend","year":"2019","unstructured":"Arend R, Martinez A, Szul T, Birrer MJ. Biomarkers in ovarian cancer: to be or not to be. Cancer. 2019;125(Suppl 24):4563\u201372.","journal-title":"Cancer"},{"key":"3082_CR8","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1158\/2159-8290.CD-21-1059","volume":"12","author":"D Hanahan","year":"2022","unstructured":"Hanahan D. Hallmarks of cancer: new dimensions. Cancer Discov. 2022;12:31\u201346.","journal-title":"Cancer Discov"},{"key":"3082_CR9","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.cmet.2022.01.007","volume":"34","author":"NN Pavlova","year":"2022","unstructured":"Pavlova NN, Zhu J, Thompson CB. The hallmarks of cancer metabolism: still emerging. Cell Metab. 2022;34:355\u201377.","journal-title":"Cell Metab"},{"key":"3082_CR10","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1016\/j.devcel.2021.04.013","volume":"56","author":"LA Broadfield","year":"2021","unstructured":"Broadfield LA, Pane AA, Talebi A, Swinnen JV, Fendt SM. Lipid metabolism in cancer: new perspectives and emerging mechanisms. Dev Cell. 2021;56:1363\u201393.","journal-title":"Dev Cell"},{"key":"3082_CR11","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1002\/cac2.12360","volume":"42","author":"X Yin","year":"2022","unstructured":"Yin X, Xu R, Song J, Ruze R, Chen Y, Wang C, et al. Lipid metabolism in pancreatic cancer: emerging roles and potential targets. Cancer Commun (Lond). 2022;42:1234\u201356.","journal-title":"Cancer Commun (Lond)"},{"key":"3082_CR12","doi-asserted-by":"publisher","first-page":"12032","DOI":"10.3390\/ijms241512032","volume":"24","author":"E Vassiliou","year":"2023","unstructured":"Vassiliou E, Farias-Pereira R. Impact of lipid metabolism on macrophage polarization: implications for inflammation and tumor immunity. Int J Mol Sci. 2023;24:12032.","journal-title":"Int J Mol Sci"},{"key":"3082_CR13","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1016\/j.cmet.2022.09.023","volume":"34","author":"M Martin-Perez","year":"2022","unstructured":"Martin-Perez M, Urdiroz-Urricelqui U, Bigas C, Benitah SA. The role of lipids in cancer progression and metastasis. Cell Metab. 2022;34:1675\u201399.","journal-title":"Cell Metab"},{"key":"3082_CR14","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1016\/j.ccr.2008.05.005","volume":"13","author":"G Kroemer","year":"2008","unstructured":"Kroemer G, Pouyssegur J. Tumor cell metabolism: cancer\u2019s Achilles\u2019 heel. Cancer Cell. 2008;13:472\u201382.","journal-title":"Cancer Cell"},{"key":"3082_CR15","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.cmet.2015.12.006","volume":"23","author":"NN Pavlova","year":"2016","unstructured":"Pavlova NN, Thompson CB. The emerging hallmarks of cancer metabolism. Cell Metab. 2016;23:27\u201347.","journal-title":"Cell Metab"},{"key":"3082_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2023.115531","volume":"211","author":"O Cadassou","year":"2023","unstructured":"Cadassou O, Jordheim LP. OXPHOS inhibitors, metabolism and targeted therapies in cancer. Biochem Pharmacol. 2023;211:115531.","journal-title":"Biochem Pharmacol"},{"key":"3082_CR17","doi-asserted-by":"publisher","first-page":"28271","DOI":"10.1074\/jbc.M204929200","volume":"277","author":"SJ Scales","year":"2002","unstructured":"Scales SJ, Hesser BA, Masuda ES, Scheller RH. Amisyn, a novel syntaxin-binding protein that may regulate SNARE complex assembly. J Biol Chem. 2002;277:28271\u20139.","journal-title":"J Biol Chem"},{"key":"3082_CR18","doi-asserted-by":"publisher","first-page":"16436","DOI":"10.3390\/ijms242216436","volume":"24","author":"M Vinci","year":"2023","unstructured":"Vinci M, Costanza C, Galati Rando R, Treccarichi S, Saccone S, Carotenuto M, et al. STXBP6 gene mutation: a new form of SNAREopathy leads to developmental epileptic encephalopathy. Int J Mol Sci. 2023;24:16436.","journal-title":"Int J Mol Sci"},{"key":"3082_CR19","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1038\/s41540-022-00243-8","volume":"8","author":"A Doostparast Torshizi","year":"2022","unstructured":"Doostparast Torshizi A, Wang K. Tissue-wide cell-specific proteogenomic modeling reveals novel candidate risk genes in autism spectrum disorders. NPJ Syst Biol Appl. 2022;8:31.","journal-title":"NPJ Syst Biol Appl"},{"key":"3082_CR20","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.3390\/ijms25021146","volume":"25","author":"L Vetri","year":"2024","unstructured":"Vetri L, Cal\u00ec F, Saccone S, Vinci M, Chiavetta NV, Carotenuto M, et al. Whole exome sequencing as a first-line molecular genetic test in developmental and epileptic encephalopathies. Int J Mol Sci. 2024;25:1146.","journal-title":"Int J Mol Sci"},{"key":"3082_CR21","doi-asserted-by":"publisher","first-page":"436","DOI":"10.3390\/brainsci11040436","volume":"11","author":"C Liu","year":"2021","unstructured":"Liu C, Hu Q, Chen Y, Wu L, Liu X, Liang D. Behavioral and gene expression analysis of Stxbp6-knockout mice. Brain Sci. 2021;11:436.","journal-title":"Brain Sci"},{"key":"3082_CR22","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1186\/s12967-025-06541-z","volume":"23","author":"T Tuersong","year":"2025","unstructured":"Tuersong T, Yong YX, Chen Y, Li PS, Shataer S, Shataer M, et al. Integrating plasma circulating protein-centered multi-omics to identify potential therapeutic targets for Parkinsonian cognitive disorders. J Transl Med. 2025;23:535.","journal-title":"J Transl Med"},{"key":"3082_CR23","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1186\/s12916-024-03583-w","volume":"22","author":"Y Qian","year":"2024","unstructured":"Qian Y, Chen S, Wang Y, Zhang Y, Zhang J, Jiang L, et al. A functional variant rs912304 for late-onset T1D risk contributes to islet dysfunction by regulating proinflammatory cytokine-responsive gene STXBP6 expression. BMC Med. 2024;22:357.","journal-title":"BMC Med"},{"key":"3082_CR24","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1007\/s00262-020-02678-6","volume":"70","author":"Y Liu","year":"2021","unstructured":"Liu Y, Huang Z, Wei Y, Zhang M, Li X, Yang S, et al. Identification of STXBP6-IRF1 positive feedback loop in regulation of PD-L1 in cancer. Cancer Immunol Immunother. 2021;70:275\u201387.","journal-title":"Cancer Immunol Immunother"},{"key":"3082_CR25","doi-asserted-by":"publisher","first-page":"42573","DOI":"10.1038\/srep42573","volume":"7","author":"G Lenka","year":"2017","unstructured":"Lenka G, Tsai MH, Lin HC, Hsiao JH, Lee YC, Lu TP, et al. Identification of methylation-driven, differentially expressed STXBP6 as a novel biomarker in lung adenocarcinoma. Sci Rep. 2017;7:42573.","journal-title":"Sci Rep"},{"key":"3082_CR26","doi-asserted-by":"publisher","first-page":"1565660","DOI":"10.1155\/2021\/1565660","volume":"2021","author":"W Wang","year":"2021","unstructured":"Wang W, Lin Y, Zhang G, Shi G, Jiang Y, Hu W, et al. circ_0002346 suppresses non-small-cell lung cancer progression depending on the regulation of the miR-582-3p\/STXBP6 Axis. Int J Genomics. 2021;2021:1565660.","journal-title":"Int J Genomics"},{"key":"3082_CR27","doi-asserted-by":"publisher","first-page":"1081510","DOI":"10.3389\/fonc.2022.1081510","volume":"12","author":"Z Cui","year":"2022","unstructured":"Cui Z, Wang J, Chen G, Li D, Cheng B, Lai Y, et al. The upregulation of CLGN in hepatocellular carcinoma is potentially regulated by hsa-miR-194-3p and associated with patient progression. Front Oncol. 2022;12:1081510.","journal-title":"Front Oncol"},{"key":"3082_CR28","first-page":"519","volume":"24","author":"Y Zhou","year":"2025","unstructured":"Zhou Y, Zhang H, Yan H, Han P, Liu Y. Immune landscape and prognostic significance of gene expression profiles in bladder cancer: insights from immune cell infiltration and risk modeling. Iran J Allergy Asthma Immunol. 2025;24:519\u201332.","journal-title":"Iran J Allergy Asthma Immunol"},{"key":"3082_CR29","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.semcancer.2019.05.012","volume":"59","author":"MK Ediriweera","year":"2019","unstructured":"Ediriweera MK, Tennekoon KH, Samarakoon SR. Role of the PI3K\/AKT\/mTOR signaling pathway in ovarian cancer: biological and therapeutic significance. Semin Cancer Biol. 2019;59:147\u201360.","journal-title":"Semin Cancer Biol"},{"key":"3082_CR30","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.ctrv.2003.07.007","volume":"30","author":"JA Fresno Vara","year":"2004","unstructured":"Fresno Vara JA, Casado E, de Castro J, Cejas P, Belda-Iniesta C, Gonz\u00e1lez-Bar\u00f3n M. PI3K\/Akt signalling pathway and cancer. Cancer Treat Rev. 2004;30:193\u2013204.","journal-title":"Cancer Treat Rev"},{"key":"3082_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2020.118513","volume":"262","author":"S Fattahi","year":"2020","unstructured":"Fattahi S, Amjadi-Moheb F, Tabaripour R, Ashrafi GH, Akhavan-Niaki H. PI3K\/AKT\/mTOR signaling in gastric cancer: epigenetics and beyond. Life Sci. 2020;262:118513.","journal-title":"Life Sci"},{"key":"3082_CR32","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1038\/s41392-021-00828-5","volume":"6","author":"Y He","year":"2021","unstructured":"He Y, Sun MM, Zhang GG, Yang J, Chen KS, Xu WW, et al. Targeting PI3K\/Akt signal transduction for cancer therapy. Signal Transduct Target Ther. 2021;6:425.","journal-title":"Signal Transduct Target Ther"},{"key":"3082_CR33","doi-asserted-by":"publisher","first-page":"173","DOI":"10.3390\/ijms22010173","volume":"22","author":"D Miricescu","year":"2020","unstructured":"Miricescu D, Totan A, Stanescu S II, Badoiu SC, Stefani C, Greabu M. PI3K\/AKT\/mTOR signaling pathway in breast cancer: from molecular landscape to clinical aspects. Int J Mol Sci. 2020;22:173.","journal-title":"Int J Mol Sci"},{"key":"3082_CR34","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202204819","volume":"10","author":"Y Tian","year":"2023","unstructured":"Tian Y, Chen ZH, Wu P, Zhang D, Ma Y, Liu XF, et al. MIR497HG-derived miR-195 and miR-497 mediate tamoxifen resistance via PI3K\/AKT signaling in breast cancer. Adv Sci (Weinh). 2023;10:e2204819.","journal-title":"Adv Sci (Weinh)"},{"key":"3082_CR35","doi-asserted-by":"publisher","first-page":"259","DOI":"10.7150\/ijbs.53795","volume":"17","author":"JC Xu","year":"2021","unstructured":"Xu JC, Chen TY, Liao LT, Chen T, Li QL, Xu JX, et al. NETO2 promotes esophageal cancer progression by inducing proliferation and metastasis via PI3K\/AKT and ERK pathway. Int J Biol Sci. 2021;17:259\u201370.","journal-title":"Int J Biol Sci"},{"key":"3082_CR36","doi-asserted-by":"publisher","DOI":"10.1111\/cpr.12739","volume":"53","author":"J Zhou","year":"2020","unstructured":"Zhou J, Jiang YY, Chen H, Wu YC, Zhang L. Tanshinone I attenuates the malignant biological properties of ovarian cancer by inducing apoptosis and autophagy via the inactivation of PI3K\/AKT\/mTOR pathway. Cell Prolif. 2020;53:e12739.","journal-title":"Cell Prolif"},{"key":"3082_CR37","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1186\/s12967-021-02781-x","volume":"19","author":"T Sun","year":"2021","unstructured":"Sun T, Bi F, Liu Z, Yang Q. TMEM119 facilitates ovarian cancer cell proliferation, invasion, and migration via the PDGFRB\/PI3K\/AKT signaling pathway. J Transl Med. 2021;19:111.","journal-title":"J Transl Med"},{"key":"3082_CR38","doi-asserted-by":"publisher","first-page":"109717","DOI":"10.1016\/j.biopha.2019.109717","volume":"123","author":"X Si","year":"2020","unstructured":"Si X, Xu F, Xu F, Wei M, Ge Y, Chenge S. CADM1 inhibits ovarian cancer cell proliferation and migration by potentially regulating the PI3K\/Akt\/mTOR pathway. Biomed Pharmacother. 2020;123:109717.","journal-title":"Biomed Pharmacother"},{"key":"3082_CR39","doi-asserted-by":"publisher","first-page":"116691","DOI":"10.1016\/j.taap.2023.116691","volume":"477","author":"A Guo","year":"2023","unstructured":"Guo A, Lin J, Zhong P, Chen J, Wang L, Lin X, et al. Phellopterin attenuates ovarian cancer proliferation and chemoresistance by inhibiting the PU.1\/CLEC5A\/PI3K-AKT feedback loop. Toxicol Appl Pharmacol. 2023;477:116691.","journal-title":"Toxicol Appl Pharmacol"},{"key":"3082_CR40","doi-asserted-by":"publisher","first-page":"67","DOI":"10.3892\/or.2025.8900","volume":"53","author":"J Yang","year":"2025","unstructured":"Yang J, He R, Zhang X, Wang X, Liu M, Liu X, et al. KLC3 activates PI3K\/AKT signaling and promotes ovarian cancer cell proliferation and migration through COL3A1. Oncol Rep. 2025;53:67.","journal-title":"Oncol Rep"},{"key":"3082_CR41","doi-asserted-by":"publisher","DOI":"10.1016\/j.redox.2024.103302","volume":"75","author":"B Sun","year":"2024","unstructured":"Sun B, Ding P, Song Y, Zhou J, Chen X, Peng C, et al. FDX1 downregulation activates mitophagy and the PI3K\/AKT signaling pathway to promote hepatocellular carcinoma progression by inducing ROS production. Redox Biol. 2024;75:103302.","journal-title":"Redox Biol"},{"key":"3082_CR42","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2023.188952","volume":"1878","author":"WY Su","year":"2023","unstructured":"Su WY, Tian LY, Guo LP, Huang LQ, Gao WY. PI3K signaling-regulated metabolic reprogramming: from mechanism to application. Biochim Biophys Acta Rev Cancer. 2023;1878:188952.","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"3082_CR43","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1186\/s12967-024-04870-z","volume":"22","author":"D Gu","year":"2024","unstructured":"Gu D, Ye M, Zhu G, Bai J, Chen J, Yan L, et al. Hypoxia upregulating ACSS2 enhances lipid metabolism reprogramming through HMGCS1 mediated PI3K\/AKT\/mTOR pathway to promote the progression of pancreatic neuroendocrine neoplasms. J Transl Med. 2024;22:93.","journal-title":"J Transl Med"},{"key":"3082_CR44","doi-asserted-by":"publisher","first-page":"12041","DOI":"10.3390\/ijms231912041","volume":"23","author":"R Zhang","year":"2022","unstructured":"Zhang R, Siu MKY, Ngan HYS, Chan KKL. Molecular biomarkers for the early detection of ovarian cancer. Int J Mol Sci. 2022;23:12041.","journal-title":"Int J Mol Sci"},{"key":"3082_CR45","doi-asserted-by":"publisher","first-page":"eadd9871","DOI":"10.1126\/sciadv.add9871","volume":"9","author":"S Chen","year":"2023","unstructured":"Chen S, Xing Z, Geng M, Zhao R, Yang X, Zhu X, et al. Macrophage fusion event as one prerequisite for inorganic nanoparticle-induced antitumor response. Sci Adv. 2023;9:eadd9871.","journal-title":"Sci Adv"},{"key":"3082_CR46","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1038\/s41419-021-03596-w","volume":"12","author":"X Luo","year":"2021","unstructured":"Luo X, Zheng E, Wei L, Zeng H, Qin H, Zhang X, et al. The fatty acid receptor CD36 promotes HCC progression through activating Src\/PI3K\/AKT axis-dependent aerobic glycolysis. Cell Death Dis. 2021;12:328.","journal-title":"Cell Death Dis"},{"key":"3082_CR47","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1038\/s41419-020-02998-6","volume":"11","author":"R Liu","year":"2020","unstructured":"Liu R, Chen Y, Liu G, Li C, Song Y, Cao Z, et al. PI3K\/AKT pathway as a key link modulates the multidrug resistance of cancers. Cell Death Dis. 2020;11:797.","journal-title":"Cell Death Dis"},{"key":"3082_CR48","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1038\/s41568-019-0216-7","volume":"20","author":"G Hoxhaj","year":"2020","unstructured":"Hoxhaj G, Manning BD. The PI3K-AKT network at the interface of oncogenic signalling and cancer metabolism. Nat Rev Cancer. 2020;20:74\u201388.","journal-title":"Nat Rev Cancer"},{"key":"3082_CR49","doi-asserted-by":"publisher","first-page":"1880","DOI":"10.1038\/s41467-020-15819-3","volume":"11","author":"J Cheng","year":"2020","unstructured":"Cheng J, Huang Y, Zhang X, Yu Y, Wu S, Jiao J, et al. TRIM21 and PHLDA3 negatively regulate the crosstalk between the PI3K\/AKT pathway and PPP metabolism. Nat Commun. 2020;11:1880.","journal-title":"Nat Commun"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-025-03082-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12032-025-03082-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-025-03082-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,22]],"date-time":"2025-11-22T16:02:16Z","timestamp":1763827336000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12032-025-03082-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,29]]},"references-count":49,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3082"],"URL":"https:\/\/doi.org\/10.1007\/s12032-025-03082-9","relation":{},"ISSN":["1559-131X"],"issn-type":[{"value":"1559-131X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,29]]},"assertion":[{"value":"16 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors report no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict to interest"}},{"value":"All procedures involving animals were conducted according to the ethical policies approved by the Institutional Animal Protection and Utilization Committee of CQMU (approval no. IACUC-CQMU-2024\u201302035). The studies involving clinical samples received approval from the Ethics Committee of the First Affiliated Hospital of CQMU (approval no. 2024-197-01).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}],"article-number":"531"}}